RE:RE:RE:RE:RE:RE:Bravo! Leede Jones Gable Yep... the straw breaking the camel's back is not the same for everyone. Bad deals when the company is struggling with unconvincing results as happened prior to 2020 is one thing. Forgivable. But squandering shareholder value after publication of groundbreaking results in Jan... that was my last straw.
Company needs to stop with the excuses and treating time as if it was free. If they can't capitalize on the current results and obvious potential immediately, they (management and BoD) need to move over. Either new team or get bid pharma to step in.
Hard decisions, but in the best interest of the company and current shareholders. Unfortunately, current management does not recognize need to change and selling to big pharma low on their list of preferences. Even more unfortunate, alternative paths not producing results.
Current team guilty of cardinal sin of business... letting perfect getting in the way of very good.